Equity Profile

TGTX

TG THERAPEUTICS INC

Health CareBiotechnology$6.1B

Mar8Fri

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EST

Company Snapshot

TG Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for patients with cancer and autoimmune diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and is crucial for long-term sustainability.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

TGTX Q2-2026 Earnings Preview

Context

Company Snapshot

TG Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for patients with cancer and autoimmune diseases. With a market cap of $6 billion, it operates in the health care sector, contributing to advancements in treatment options that could significantly impact patient care.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+113.34%

Avg Stock Reaction

+1.32%

Last Quarter Recap

In the last quarter, TG Therapeutics reported an EPS of $0.12, falling short of the expected $0.23, resulting in a 48.5% surprise. Despite the miss, the stock saw a notable increase of 16.26% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for this quarter are mixed, with no consensus estimates available. Investors are keen to see if the company can improve its earnings performance after recent misses.

Bull Case

The optimistic view hinges on the potential for a strong recovery in EPS and revenue growth, which could signal effective product development and market acceptance.

Bear Case

On the flip side, continued earnings misses could lead to diminished investor confidence and further stock price declines.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to previous estimates?

Given the company's recent history of EPS misses, this number will be critical in assessing management's performance and future outlook.

What are the revenue figures and growth expectations for the upcoming quarters?

Revenue growth is essential for sustaining investor interest and confidence, especially after recent earnings disappointments.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a rebound in EPS due to recent product advancements that have not yet been fully reflected in analyst models.

Supporting Evidence

The options market is pricing a relatively low move of 3.57%, suggesting limited expectations for significant changes.

Recent stock performance following earnings misses indicates a potential for recovery that analysts may not be fully accounting for.

Key Risk

If the EPS exceeds $0.25, it could challenge the current bearish sentiment and shift market perceptions.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter is pivotal as the company seeks to recover from a series of earnings misses, and the market is closely watching for signs of improvement.

Bull Confirmed If

An EPS of $0.25 or higher would confirm the bull case, indicating a turnaround in profitability.

Bear Confirmed If

An EPS below $0.10 would confirm the bear case, suggesting ongoing challenges in the company's financial performance.

Pre-Earnings Positioning

Options Market

Implied Move

±3.57%

Historical Avg

±12.3%

Pricing cheap

The options market is pricing a modest move of about 3.57%, indicating that traders expect limited volatility around the earnings report.

Options are pricing ±3.6% while TGTX has averaged ±12.3% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.5%

30d HV

59.8%

Calls (49K)P/C Ratio: 0.50Puts (29K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If TG Therapeutics beats expectations, history suggests a potential stock increase of around 10.28%, confirming a positive turnaround narrative.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors digest management's commentary on future growth.

Miss

Should the company miss again, history indicates a likely decline of about 4.05%, reinforcing concerns about its financial trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements and their expected impact on revenue.
2Management's commentary on cost management strategies and their effect on profitability.
3Insights into market demand for current therapies and any potential new indications.
4Details on partnerships or collaborations that could enhance growth prospects.
5Guidance on future earnings expectations and how they align with market trends.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Ross Stores, Inc.

Company Snapshot

TG Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for patients with cancer and autoimmune diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and is crucial for long-term sustainability.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

TGTX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+113.34%

Avg Stock Reaction

+1.32%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for this quarter are mixed, with no consensus estimates available. Investors are keen to see if the company can improve its earnings performance after recent misses.

Bull Case

The optimistic view hinges on the potential for a strong recovery in EPS and revenue growth, which could signal effective product development and market acceptance.

Bear Case

On the flip side, continued earnings misses could lead to diminished investor confidence and further stock price declines.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to previous estimates?

Given the company's recent history of EPS misses, this number will be critical in assessing management's performance and future outlook.

What are the revenue figures and growth expectations for the upcoming quarters?

Revenue growth is essential for sustaining investor interest and confidence, especially after recent earnings disappointments.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a rebound in EPS due to recent product advancements that have not yet been fully reflected in analyst models.

Supporting Evidence

The options market is pricing a relatively low move of 3.57%, suggesting limited expectations for significant changes.

Recent stock performance following earnings misses indicates a potential for recovery that analysts may not be fully accounting for.

Key Risk

If the EPS exceeds $0.25, it could challenge the current bearish sentiment and shift market perceptions.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter is pivotal as the company seeks to recover from a series of earnings misses, and the market is closely watching for signs of improvement.

Bull Confirmed If

An EPS of $0.25 or higher would confirm the bull case, indicating a turnaround in profitability.

Bear Confirmed If

An EPS below $0.10 would confirm the bear case, suggesting ongoing challenges in the company's financial performance.

Pre-Earnings Positioning

Options Market

Implied Move

±3.57%

Historical Avg

±12.3%

Pricing cheap

The options market is pricing a modest move of about 3.57%, indicating that traders expect limited volatility around the earnings report.

Options are pricing ±3.6% while TGTX has averaged ±12.3% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.5%

30d HV

59.8%

Calls (49K)P/C Ratio: 0.50Puts (29K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If TG Therapeutics beats expectations, history suggests a potential stock increase of around 10.28%, confirming a positive turnaround narrative.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors digest management's commentary on future growth.

Miss

Should the company miss again, history indicates a likely decline of about 4.05%, reinforcing concerns about its financial trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements and their expected impact on revenue.
2Management's commentary on cost management strategies and their effect on profitability.
3Insights into market demand for current therapies and any potential new indications.
4Details on partnerships or collaborations that could enhance growth prospects.
5Guidance on future earnings expectations and how they align with market trends.